Three-Year Switch Exclusivity Included In Amended EU Drug Legislation
This article was originally published in The Tan Sheet
Executive Summary
Three years of data exclusivity for Rx-to-OTC switch candidates and new indications of approved medicinal products would be available to European drug marketers under legislation currently making its way through the European regulatory process